Regeneron Pharmaceuticals Inc (REGN) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, inclu...
Regeneron Pharmaceuticals Inc (REGN) currently trades at a P/E ratio of 19.39 (historical range: 11.94–31.61, median: 17.08), placing it at the 86th percentile — expensive relative to its history, P/S ratio of 5.75 (range: 3.81–10.13, 64th percentile — above its historical average), EV/EBITDA of 122.89 (range: 16.53–130.33, 97th percentile).
Regeneron Pharmaceuticals Inc appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 19.39 | 11.94 | 17.08 | 31.61 | 86th | expensive relative to its history |
| P/S Ratio | 5.75 | 3.81 | 5.50 | 10.13 | 64th | above its historical average |
| EV/EBITDA | 122.89 | 16.53 | 33.34 | 130.33 | 97th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.03 | 0.05 | 3th | expensive relative to its history |